Land: Verenigde Staten
Taal: Engels
Bron: NLM (National Library of Medicine)
Lamotrigine (UNII: U3H27498KS) (Lamotrigine - UNII:U3H27498KS)
Taro Pharmaceuticals U.S.A., Inc.
Lamotrigine
Lamotrigine 5 mg
ORAL
PRESCRIPTION DRUG
Adjunctive Therapy: Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: - partial-onset seizures. - primary generalized tonic-clonic (PGTC) seizures. - generalized seizures of Lennox-Gastaut syndrome. Monotherapy: Lamotrigine is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. Lamotrigine is indicated for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (aged 1
Lamotrigine Tablets (Chewable, Dispersible), 5 mg: White, oval tablets, engraved with "L5" on one side and "T" on the other side. Lamotrigine Tablets (Chewable, Dispersible), 25 mg: White, round tablets, engraved with "L25" on one side and "T" on the other side. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature] in a dry place.
Abbreviated New Drug Application
LAMOTRIGINE- lamotrigine tablet, chewable Taro Pharmaceuticals U.S.A., Inc. ---------- MEDICATION GUIDE Lamotrigine (la moe' tri jeen) Tablets (Chewable, Dispersible) Read this Medication Guide before you start taking lamotrigine and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. If you have questions about lamotrigine, ask your healthcare provider or pharmacist. What is the most important information I should know about lamotrigine tablets (chewable, dispersible)? 1. Lamotrigine tablets (chewable, dispersible) may cause a serious skin rash that may cause you to be hospitalized or even cause death. There is no way to tell if a mild rash will become more serious. A serious skin rash can happen at any time during your treatment with lamotrigine, but is more likely to happen within the first 2 to 8 weeks of treatment. Children aged between 2 and 16 years have a higher chance of getting this serious skin rash while taking lamotrigine. The risk of getting a serious skin rash is higher if you: • take lamotrigine while taking valproate [DEPAKENE® (valproic acid) or DEPAKOTE® (divalproex sodium)]. • take a higher starting dose of lamotrigine than your healthcare provider prescribed. • increase your dose of lamotrigine faster than prescribed. Call your healthcare provider right away if you have any of the following: • a skin rash • blistering or peeling of your skin • hives • painful sores in your mouth or around your eyes These symptoms may be the first signs of a serious skin reaction. A healthcare provider should examine you to decide if you should continue taking lamotrigine. 2. Other serious reactions, including serious blood problems or liver problems. Lamotrigine can also cause other types of allergic reactions or serious problems that may affect organs and other parts of your body like your liver or blood cells. You may or may not have a rash with these types of re Lees het volledige document
LAMOTRIGINE- LAMOTRIGINE TABLET, CHEWABLE TARO PHARMACEUTICALS U.S.A., INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE LAMOTRIGINE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR LAMOTRIGINE. LAMOTRIGINE TABLETS (CHEWABLE, DISPERSIBLE), FOR ORAL USE INITIAL U.S. APPROVAL: 1994 WARNING: SERIOUS SKIN RASHES _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ CASES OF LIFE-THREATENING SERIOUS RASHES, INCLUDING STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS, AND/OR RASH-RELATED DEATH HAVE BEEN CAUSED BY LAMOTRIGINE. THE RATE OF SERIOUS RASH IS GREATER IN PEDIATRIC PATIENTS THAN IN ADULTS. ADDITIONAL FACTORS THAT MAY INCREASE THE RISK OF RASH INCLUDE: COADMINISTRATION WITH VALPROATE. EXCEEDING RECOMMENDED INITIAL DOSE OF LAMOTRIGINE. EXCEEDING RECOMMENDED DOSE ESCALATION FOR LAMOTRIGINE. (5.1) BENIGN RASHES ARE ALSO CAUSED BY LAMOTRIGINE; HOWEVER, IT IS NOT POSSIBLE TO PREDICT WHICH RASHES WILL PROVE TO BE SERIOUS OR LIFE THREATENING. LAMOTRIGINE SHOULD BE DISCONTINUED AT THE FIRST SIGN OF RASH, UNLESS THE RASH IS CLEARLY NOT DRUG RELATED. (5.1) RECENT MAJOR CHANGES Dosage and Administration (2.1, 2.2, 2.4) 12/2014 Warnings and Precautions, Laboratory Tests (5.14) 3/2015 INDICATIONS AND USAGE Lamotrigine is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. (1.1) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED. (1.1) Bipolar disorder in patients aged 18 years and older: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2) DOSAGE AND ADMINISTRATION Dosing is based on conc Lees het volledige document